Drugs / apomine
apomine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00004049 | Apr 1999 → ? | cancer of unknown primary site | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00003822 | Aug 1998 → ? | cancer of unknown primary site | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00078026 | Aug 2003 → Dec 2004 | postmenopausal osteoporosis | Genzyme, a Sanofi Company | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | apomine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004049 ↗ |
| Known as | SR 9223I | ChEMBL registry synonym — accepted as the source's own label CHEMBL4639024 ↗ |
| Known as | SR-45023A | ChEMBL registry synonym — accepted as the source's own label CHEMBL4639024 ↗ |
| Modality | Small molecule | — CHEMBL4639024 ↗ |
| Route | Oral | “Patients receive oral SR-45023A twice daily for 14 days” NCT00003822 ↗ |